ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Rhea-AI Summary
Oragenics (NYSE American: OGEN) filed its Form 10-K for the fiscal year ended December 31, 2025 and provided a shareholder update on 2025 milestones and Q1 2026 progress.
Key 2025 highlights include a $16.5 million capital raise, repayment of a $3.0 million promissory note, an 11% reduction in operating expenses, US cGMP manufacturing engagement, CRO contracting for a Phase IIa trial, and a partnership with Receptor.AI. Q1 2026 updates include HREC approval in Australia, initial site initiation visit, and IND readiness work with DUCK FLATS Pharma.
Positive
- Capital raise of $16.5 million strengthened balance sheet
- Repaid $3.0 million promissory note—no debt
- HREC approval secured enabling Australian Phase IIa dosing
- US cGMP manufacturing contracted with Sterling Pharma Solutions
- CRO engaged to run Phase IIa across three Australian sites
Negative
- Net cash used in operations ~$9 million in 2025
- R&D and overhead remain primary cost drivers despite 11% reduction
News Market Reaction – OGEN
On the day this news was published, OGEN declined 3.01%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $99K from the company's valuation, bringing the market cap to $3M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
While OGEN was down 9.71%, peers were mixed: XBIO up 17.36%, APVO up 5.22%, QNRX up 3.93%, and ONCO down 12.3%. This pattern points to stock-specific dynamics rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 12 | Phase IIa activation | Positive | +8.5% | Announced first site initiation visit for ONP-002 Phase IIa in Australia. |
| Mar 11 | CNS platform expansion | Positive | -9.9% | Outlined plans to acquire CNS assets to extend intranasal platform. |
| Mar 10 | HREC trial approval | Positive | +2.2% | Received final HREC approval for ONP-002 Phase IIa concussion trial. |
| Feb 09 | Market opportunity preview | Positive | -5.2% | Previewed 2026 milestones and outlined ONP-002 market opportunity. |
| Feb 03 | DUCK FLATS partnership | Positive | -7.2% | Partnered with DUCK FLATS Pharma for FDA IND readiness and trial design. |
Recent news has often produced mixed or contrary price reactions; several positive clinical and strategic updates were followed by both gains and notable selloffs.
Over the last few months, Oragenics has steadily advanced ONP-002 with HREC approval in Australia, Phase IIa site activation, and engagement of DUCK FLATS Pharma for U.S. IND planning. It also highlighted a fully funded 40-patient Phase IIa trial and a targeted concussion market opportunity. Price reactions were inconsistent, with some clinical milestones (e.g., Mar 12) lifting shares, while other seemingly positive strategic updates saw declines. Today’s 10-K and shareholder update consolidate these themes.
Regulatory & Risk Context
An effective Form S-3 shelf filed on 2026-01-22 would allow Oragenics to offer and sell up to $100,000,000 of securities, including $34,156,040 carried over from a prior shelf. Under General Instruction I.B.6, primary offerings are limited to no more than one-third of its public float in any twelve-month period unless its float rises to at least $75.0 million.
Market Pulse Summary
This announcement details a year of restructuring and clinical progress, including a $16.5 million capital raise, full repayment of $3.0 million in debt, and advancement of ONP-002 into Phase IIa with HREC approval in Australia. The new $100,000,000 shelf registration and ongoing cash use underscore financing risk alongside clinical execution. Investors may watch trial enrollment, timing of the planned IND filing, and any future use of the shelf for further context.
Key Terms
Phase IIa medical
Human Research Ethics Committee medical
HREC medical
at-the-market financial
shelf registration statement regulatory
reverse stock split financial
Schedule 13G regulatory
AI-generated analysis. Not financial advice.
REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT
SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal delivery technology, today announced the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission. In conjunction with this filing, the Company is providing a shareholder update on key operational and clinical milestones achieved during 2025 and progress made in the first quarter of 2026.
The Annual Report on Form 10-K, including audited financial statements for the fiscal year ended December 31, 2025, is available on the SEC's EDGAR system at www.sec.gov and on the Company's investor relations website at www.ir.oragenics.com.
2025: A YEAR OF DECISIVE TRANSFORMATION
Fiscal year 2025 represented a pivotal year in Oragenics evolution — from a company managing legacy challenges to a focused, execution-oriented clinical-stage biotechnology company with a clear path forward. Key operational milestones achieved in 2025 include:
- NYSE American Compliance Restored: Regained full listing compliance, reflecting improved governance and shareholder alignment
- CRO Engaged: Contracted a qualified clinical research organization to lead Phase IIa trial operations across three Australian sites
- US based Drug Manufacturing: Moved drug manufacturing out of China and to the United States, contracting Sterling Pharma Solutions for FDA cGMP (Current Good Manufacturing Practice) manufacturing in Cary, North Carolina.
- Receptor.AI Partnership Established: Formalized a strategic partnership with Receptor.AI to leverage artificial intelligence in central nervous system (CNS) drug discovery, expanding the Company's pipeline development capability beyond ONP-002
Key financial milestones achieved in 2025 include:
$16.5 Million Capital Raise: Completed a successful financing that strengthened the Company's balance sheet and funded advancement of ONP-002 through Phase IIa clinical trials in Australia- No Debt: Repaid in full the
$3.0 million promissory note - Financial Stewardship: Reduced operating expenses by
11% year over year with R&D expenses and overhead salaries and wages as the largest drivers of this expense reduction. - Cash Position: Net cash used in operations was approximately
$ 9 million and net cash from financing was approximately$16.8 million .
2026 PROGRESS — FIRST QUARTER
Building on 2025 momentum, the Company made the following material advances in early 2026:
- HREC Ethics Approval Received: Obtained Human Research Ethics Committee (HREC) approval in Australia — the final regulatory clearance required to begin patient dosing in the Phase IIa trial of ONP-002 in Australia
- Phase IIa Site Initiation Underway: Completed the first site initiation visit (SIV) at the initial Australian clinical trial site; two additional sites advancing through final Research Governance Office reviews
- Patient Enrollment Positioning: All three sites in Australia expected to complete RGO review in the near term, at which point patient enrollment and dosing will commence
- CNS Portfolio Strategy Activated: The Company is actively pursuing discussions with potential partners regarding the acquisition of additional CNS assets synergistic with ONP-002 and the Company's intranasal delivery platform
- US Clinical Trial Strategy: Engaged DUCK FLATS Pharma as its U.S. IND readiness and regulatory execution partner to support FDA-facing preparation and clinical trial design
- Annual Report Filed: Form 10-K filed for fiscal year ended December 31, 2025
2026 STRATEGIC PRIORITIES
- Enroll and dose patients in the Phase IIa clinical trial of ONP-002 in Australia
- File an IND with the FDA to enable a U.S.-based clinical trials
- Advance CNS portfolio expansion strategy by evaluating and pursuing synergistic asset acquisition opportunities
"2025 was the year we reset this company — financially, operationally, and strategically,” reported Janet Huffman, the Company’s Chief Executive Officer. “We raised capital, restored compliance, resolved a material legacy liability, and built the partnerships and infrastructure to compete at a higher level. None of that was easy, and none of it was accidental. It was the result of disciplined execution by a team that believes deeply in what ONP-002 can do for the 69 million people worldwide who suffer concussions every year with no approved pharmacological treatment available to them. 2026 is not about resetting. It is about executing. We are in the clinic. Patients will be dosed. And we are actively exploring the expansion of our CNS platform."
FORWARD-LOOKING STATEMENTS
This communication contains "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements." Forward-looking statements include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our product candidates, including without limitation ONP-002 and our proprietary nasal device; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct, interim results announcements and outcomes of our clinical trials for our product candidates, including ONP-002 for the treatment of concussion and mTBI; our acquisition strategy and prospects; and our ability to finance our operations. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words "believe," "expect," "anticipate," "intend," "estimate," "project," "potential," "may," "will," "could," "should," and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our most recent Form 10-K, Form 10-Q and other filings we make with the U.S. Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. All information we set forth in this press release is as of the date hereof. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.
ABOUT ORAGENICS
Oragenics, Inc. (NYSE American: OGEN) is a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal drug delivery technology. The Company's lead candidate, ONP-002, is a first-in-class intranasal neurosteroid in Phase IIa clinical development for the treatment of concussion and mild traumatic brain injury (mTBI) — conditions affecting an estimated 69 million people globally each year with no approved pharmacological treatment. Oragenics intranasal delivery platform is designed to enable rapid, non-invasive delivery of therapeutics directly to the brain bypassing the blood-brain barrier. The Company is exploring broadening its CNS pipeline strategy through both internal development and strategic business development. For more information, visit www.oragenics.com.
Investor Contact:
800-383-4880
ir@oragenics.com
FAQ
What did Oragenics (OGEN) report in its Form 10-K for fiscal 2025?
How will Oragenics' $16.5 million financing affect OGEN's development plans?
What is the clinical status of ONP-002 for OGEN as of March 17, 2026?
Why did Oragenics move drug manufacturing to the U.S. and who is the manufacturer?
What are Oragenics' near-term priorities for 2026 and how do they affect OGEN shareholders?
